Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease

de Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections. Verh K Acad Geneeskd Belg 1996; 58: 19–47.

Donne A.J. , Hampson I. , He X.T. Effects of cidofovir on a novel cell-based test system for recurrent respiratory papillomatosis. Head Neck 2007; 29: 741–750.

Araya C.E. , Lew J.F. , Fennell R.S. , Neiberger R.E. , Dharnidharka V.R. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant 2008; 12: 790–795.

Yoshizaki T. , Wakisaka N. , Kondo S. Treatment of locally recurrent Epstein–Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J Med Virol 2008; 80: 879–882.

Anderson E.J. , Guzman-Cottrill J.A. , Kletzel M. High-risk adenovirus-infected pediatric allogeneic haematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant 2008; 12: 219–227.

Cusack C. , Fitzgerald D. , Clayton T.M. Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11-year-old girl. Pediatr Dermatol 2008; 25: 387–389.

Derkay C.S. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 1995; 121: 1386–1391.

Inglis A.F. Jr. , Cidofovir and the black box warning. Ann Otol Rhinol Laryngol 2005; 114: 834–835.

Abdulkarim B. , Sabri S. , Deutsch E. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002; 21: 2334–2346.

Sirianni N. , Wang J. , Ferris R.L. Antiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol 2005; 41: 423–428.

Kramata P. , Votruba I. , Otova B. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol 1996; 49: 1005–1011.

De Clercq E. , Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4: 928–940.

Shin K.H. , Park K.H. , Hong H.J. Prevalence of microsatellite instability, inactivation of mismatch repair genes, p53 mutation, and human papillomavirus infection in Korean oral cancer patients. Int J Oncol 2002; 21: 297–302.

Shin K.H. , Ahn J.H. , Kang M.K. HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and -independent pathways. Int J Oncol 2006; 28: 209–215.

Band V. , Dalal S. , Delmolino L. Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J 1993; 12: 1847–1852.

Duensing S. , Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157–162.

Hampson L. , Kitchener H.C. , Hampson I.N. Specific HIV protease inhibitors inhibit the ability of HPV 16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.Antivir Ther 2006; 11: 813–825.

Vandesompele J. , De P.K. , Pattyn F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.

Brown J.M. , Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5: 231–237.

Lalezari J.P. , Drew W.L. , Glutzer E. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995; 171: 788–796.

Albright J.T. , Pransky S.M. Update on the use of cidofovir for managing recurrent respiratory papillomatosis. ENT News 2003; 12: 71–73.

Mammas I.N. , Sourvinos G. , Michael C. Human papilloma virus in hyperplastic tonsillar and adenoid tissues in children. Pediatr Infect Dis J 2006; 25: 1158–1162.

Sisk J. , Schweinfurth J.M. , Wang X.T. Presence of human papillomavirus DNA in tonsillectomy specimens. Laryngoscope 2006; 116: 1372–1374.

Smith E.M. , Pignatari S.S. , Gray S.D. Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction. Arch Otolaryngol Head Neck Surg 1993; 119: 554–557.

Mori N. , Krensky A.M. , Ohshima K. Elevated expression of CCL5/RANTES in adult T-cell leukaemia cells: possible transactivation of the CCL5 gene by human T-cell leukemia virus type I tax. Int J Cancer 2004; 111: 548–557.

Uchihara J.N. , Krensky A.M. , Matsuda T. Transactivation of the CCL5/RANTES gene by Epstein–Barr virus latent membrane protein 1. Int J Cancer 2005; 114: 747–755.

Niwa Y. , Akamatsu H. , Niwa H. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001; 7: 285–289.

Schall T.J. , Bacon K. , Toy K.J. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669–671.

Pritchard J. , Han R. , Horst N. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 2003; 170: 6348–6354.

Burrow S. , Andrulis I.L. , Pollak M. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998; 69: 21–27.

Ulfarsson E. , Karstrom A. , Yin S. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin Cancer Res 2005; 11: 4674–4680.

Girnita L. , Girnita A. , Brodin B. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 2000; 60: 5278–5283.

Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55: 249–252.

Larsson O. , Girnita A. , Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2005; 92: 2097–2101.

Shellenberger T.D. , Mazumdar A. , Henderson Y. Headpin: a serpin with endogenous and exogenous suppression of angiogenesis. Cancer Res 2005; 65: 11501–11509.

Garcia M.J. , Pole J.C. , Chin S.F. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 2005; 24: 5235–5245.

Ivanov I. , Lo K.C. , Hawthorn L. Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells. Oncogene 2007; 26: 2873–2884.

Chen Y. , Pacyna-Gengelbach M. , Deutschmann N. Homeobox gene HOP has a potential tumor suppressive activity in human lung cancer. Int J Cancer 2007; 121: 1021–1027.

Lemaire F. , Millon R. , Muller D. Loss of HOP tumour suppressor expression in head and neck squamous cell carcinoma. Br J Cancer 2004; 91: 258–261.

Zhao L.Y. , Liao D. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. J Virol 2003; 77: 13171–13181.

Jang S.I. , Kalinin A. , Takahashi K. Characterization of human epiplakin: RNAi-mediated epiplakin depletion leads to the disruption of keratin and vimentin IF networks. J Cell Sci 2005; 118: 781–793.

Goto M. , Sumiyoshi H. , Sakai T. Elimination of epiplakin by gene targeting results in acceleration of keratinocyte migration in mice. Mol Cell Biol 2006; 26: 548–558.

Lott D.G. , Krakovitz P.R. Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. Laryngoscope 2009; 119: 567–570.

Eisenbeis J.F. , Sappington J.M. The effect of cidofovir injection concurrent with surgical resection for adult onset recurrent respiratory papillomatosis. Laryngoscope 2009; 119 Suppl 1: S96.

Carvalho C.M. , Huot L. , Charlois A.L. Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients. Acta Otolaryngol 2009; 129: 462–470.

Broekema F.I. , Dikkers F.G. Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 2008; 265: 871–879.

Poetker D.M. , Patel N.J. , Kerschner J.E. Cidofovir modulated gene expression in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2008; 72: 1385–1392.

McMurray J.S. , Connor N. , Ford C.N. Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol 2008; 117: 477–483.

Lewis T.E. , Milam T.D. , Klingler D.W. Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer. Urol Oncol 2005; 23: 407–412.

Wirtenberger M. , Tchatchou S. , Hemminki K. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. Carcinogenesis 2006; 27: 593–598.

Capurso G. , Lattimore S. , Crnogorac-Jurcevic T. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 2006; 13: 541–558.

Riker A.I. , Enkemann S.A. , Fodstad O. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008; 1: 13.

Cahill D.P. , Lengauer C. , Yu J. Mutations of mitotic checkpoint genes in human cancers. Nature 1998; 392: 300–303.

Yoon S. , Molloy M.J. , Wu M.P. C6ORF32 is upregulated during muscle cell differentiation and induces the formation of cellular filopodia. Dev Biol 2007; 301: 70–81.

Luboshits G. , Shina S. , Kaplan O. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999; 59: 4681–4687.

Vaday G.G. , Peehl D.M. , Kadam P.A. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66: 124–134.

Ek S. , Bjorck E. , Hogerkorp C.M. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer 2006; 118: 2092–2097.

Aldinucci D. , Lorenzon D. , Cattaruzza L. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769–776.

Kashibuchi K. , Tomita K. , Schalken J.A. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 2007; 14: 789–794.

Fujita M. , Furukawa Y. , Tsunoda T. Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor complex, in colorectal carcinomas. Cancer Res 2001; 61: 7722–7726.

Xiang Q. , Fan S.Q. , Li J. Expression of connexin43 and connexin45 in nasopharyngeal carcinoma. Ai Zheng 2002; 21: 593–596. [Chinese].

Hayashi E. , Kuramitsu Y. , Okada F. Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 2005; 5: 1024–1032.

Suomela S. , Cao L. , Bowcock A. Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J Invest Dermatol 2004; 122: 717–721.

Taguchi T. , Kato Y. , Baba Y. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncol Rep 2004; 11: 421–426.

Dong A. , Kong M. , Ma Z. Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 497–504.

Liu W. , Bloom D.A. , Cance W.G. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29: 1096–1107.

Sroka I.C. , McDaniel K. , Nagle R.B. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. Prostate 2008; 68: 463–476.

Oshikawa K. , Yanagisawa K. , Ohno S. Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med 2002; 165: 1005–1009.

Shimada H. , Kuboshima M. , Shiratori T. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 2007; 30: 97–103.

Kim T.J. , Choi J.J. , Kim W.Y. Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer. Cancer Sci 2008; 99: 31–38.

Pinheiro C. , Longatto-Filho A. , Ferreira L. Increasing Expression of Monocarboxylate Transporters 1 and 4 Along Progression to Invasive Cervical Carcinoma. Int J Gynecol Pathol 2008; 27: 568–574.

Pinheiro C. , Longatto-Filho A. , Scapulatempo C. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 2008; 452: 139–146.

Raman M. , Earnest S. , Zhang K. TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 2007; 26: 2005–2014.

Park M. , Dean M. , Cooper C.S. Mechanism of met oncogene activation. Cell 1986; 45: 895–904.

Liu Q. , Gao J. , Chen X. HBP21: A Novel Member of TPR Motif Family, as a Potential Chaperone of Heat Shock Protein 70 in Proliferative Vitreoretinopathy (PVR) and Breast Cancer. Mol Biotechnol 2008; 40: 231–240.

Jackson R.S. , Cho Y.J. , Liang P. TIS11D is a candidate pro-apoptotic p53 target gene. Cell Cycle 2006; 5: 2889–2893.